INVESTORS & MEDIA
News Release
Regeneron and Sanofi to Present New Analyses from the Praluent® (alirocumab) Injection ODYSSEY Clinical Trial Program at the AHA Scientific Sessions 2017
New analyses from the ODYSSEY ESCAPE trial evaluating treatment of Praluent in high-risk patients with heterozygous familial hypercholesterolemia (HeFH) undergoing apheresis therapy will be presented. Additional ODYSSEY clinical trial program data include a post-hoc analysis of three pooled ODYSSEY Phase 3 studies evaluating efficacy and safety data by race and ethnicity, and results of the ODYSSEY Open-Label Extension study observing long-term adherence to Praluent.
Key poster presentations at AHA Scientific Sessions 2017 from the ODYSSEY clinical trial program and other studies include:
Praluent Data
- Characteristics of Patients with < 15% Reduction in Low-Density Lipoprotein Cholesterol with Alirocumab (Bays)
- Abstract # S2114
Sunday, November 12 ,3:15 PM - 4:30 PM PT - Effect of Apheresis on Alirocumab and PCSK9 Concentrations in the ODYSSEY ESCAPE Study (Moriarty)
- Abstract # M5005
Monday, November 13 ,3:00 PM - 4:15 PM PT - Impact of Age on the Efficacy and Safety of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia (Santos)
- Abstract # T2064
Tuesday, November 14 ,10:30 AM - 11:45 AM PT - High Level of Adherence to Alirocumab and Concomitant Background Treatments for Patients with Heterozygous Familial Hypercholesterolemia in the ODYSSEY Open-Label Extension Study (Farnier)
- Abstract # T2144
Tuesday, November 14 ,10:30 AM - 11:45 AM PT - Alirocumab Efficacy and Safety by Race and Ethnicity: Analysis From Three ODYSSEY Phase 3 Trials (Ferdinand)
- Abstract # T2063
Tuesday, November 14 ,10:30 AM - 11:45 AM PT - Predictive Factors of the Magnitude of Response to Alirocumab Dose Increase in Patients with Dyslipidemia (Ray)
- Abstract # T2138
Tuesday, November 14 ,10:30 AM - 11:45 AM PT
Other Data of Interest
- PCSK9 Inhibitors: Patient-Reported Barriers to Medication Initiation & Persistence (Navar)
- Abstract # S2112
Sunday, November 12 ,3:15 PM - 4:30 PM PT - Statin Utilization and Side Effects Among Adults Over Age 75: Insights From the PALM Registry (Nanna)
- Abstract # M2198
Monday, November 13 ,3:00 PM - 4:15 PM PT - Associations of Provider Knowledge and Beliefs Regarding Lipid Management With Statin Therapy Use and Lipid Outcomes (Lowenstern)
- Abstract # T2113
Tuesday, November 14 ,10:30 AM - 11:45 AM PT - Statin Decision-Making Since the 2013 AHA/ACC Cholesterol Guidelines: Do Clinicians Do What They Say? (Lowenstern)
- Abstract # T2109
Tuesday, November 14 ,10:30 AM - 11:45 AM PT
Additional information on the AHA Scientific Sessions 2017 is available on the meeting website.
About Praluent
Praluent inhibits the binding of PCSK9 (proprotein convertase subtilisin/kexin type 9) to the LDL receptor and thereby increases the number of available LDL receptors on the surface of liver cells, which results in lower LDL-C levels in the blood.
Praluent is approved in more than 50 countries worldwide, including the
Important Safety Information for the
Do not use Praluent if you are allergic to alirocumab or to any of the ingredients in Praluent.
Before you start using Praluent, tell your healthcare provider about all your medical conditions, including allergies, and if you are pregnant or plan to become pregnant or if you are breastfeeding or plan to breastfeed.
Tell your healthcare provider or pharmacist about any prescription and over-the-counter medicines you are taking or plan to take, including natural or herbal remedies.
Praluent can cause serious side effects, including allergic reactions that can be severe and require treatment in a hospital. Call your healthcare provider or go to the nearest hospital emergency room right away if you have any symptoms of an allergic reaction including a severe rash, redness, severe itching, a swollen face, or trouble breathing.
The most common side effects of Praluent include: redness, itching, swelling, or pain/tenderness at the injection site, symptoms of the common cold, and flu or flu-like symptoms. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
Talk to your doctor about the right way to prepare and give yourself a Praluent injection and follow the "Instructions for Use" that comes with Praluent.
You are encouraged to report negative side effects of prescription drugs to the
Visit www.fda.gov/medwatch or call 1-800-
Please click here for the full Prescribing Information
About Sanofi
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, and provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Sanofi, Empowering Life
About
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led by physician-scientists for nearly 30 years, our unique ability to repeatedly and consistently translate science into medicine has led to six
Regeneron is accelerating and improving the traditional drug development process through its proprietary VelociSuite® technologies, including VelocImmune® to yield optimized fully-human antibodies, and ambitious initiatives such as the Regeneron Genetics Center, one of the largest genetics sequencing efforts in the world.
For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, including the patent litigation relating to Praluent, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, unexpected safety, quality or manufacturing issues, decisions by regulatory authorities, such as the
Regeneron Forward-Looking Statements and Use of Digital Media
This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of
Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).
Contact Sanofi:
Media Relations Tel: +1 (908) 981-8745 Mobile: +1 (908) 205-2572 |
Investor Relations Tel. +33 (0) 1 53 77 45 45 |
Contact Regeneron:
Media Relations Tel: + 1 (914) 847-3456 Mobile: +1 (914) 260-8788 |
Investor Relations Tel.: +1 (914) 847-5126
|
SOURCE
News Provided by Acquire Media